The pro-inflammatory role of cytokines in the mechanism of atherosclerosis;Ruolo delle citochine pro-infiammatorie nei meccanismi patogenetici dell'aterosclerosi coronarica

Giornale Italiano di Cardiologia

Volumn 7, Issue 9, 2006, Pages 594-603

  Correale, Michele ^a   Brunetti, Natale Daniele ^a   Di Biase, Matteo ^a  

^a Univ degli Study di Foggy   (Italy)

Author keywords

Coronary artery disease; Cytokines; Inflammation

Indexed keywords

ALPHA INTERFERON; ATORVASTATIN; BETA INTERFERON; C REACTIVE PROTEIN; CD40 LIGAND; CERIVASTATIN; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; LYMPHOTOXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; STEM CELL FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; ATHEROGENESIS; CORONARY ARTERY ATHEROSCLEROSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; HUMAN; INFLAMMATION; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; TH1 CELL;

ACUTE DISEASE; ANGINA, UNSTABLE; ATHEROSCLEROSIS; CYTOKINES; HUMANS; INFLAMMATION; MYOCARDIAL INFARCTION; SYNDROME;

EID: 33845499310     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Chockalingam A, Balaguer-Vintro I. Impeding global pandemic of cardiovascular disease; challenges and opportunities for the prevention and control of cardiovascular diseases in developing countries and economies in transition. Barcellona: Prous Science, 1999.
2. American Heart Association. 1999 Heart and stroke statistical update. Dallas, TX: American Heart Association, 1998.
3. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
4. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000; 36: 970-1062.
5. Cotran RS, Kumar V, Robbins M. Le basi patologiche delle malattie. V edizione. Padova: Piccin, 1994.
6. Wayne AR, Schlant RC, Fuster V, O' Rourke RA, Roberts R, Sonnenblink EH. Hurst - Il cuore. Arterie e vene. IX edizione. Milano: McGraw-Hill, 1999.
7. Li H, Cybulsky MI, Gimbrone MA Jr, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine regulatable mononuclear leukocyte adhesion molecole, in rabbit aortic endothelium. Arterioscler Thromb 1993; 13: 197-204.
8. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001; 107: 1255-62.
9. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 1996; 93: 10417-22.
10. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96: 60-8.
11. Nagel T, Resnick N, Atkinson WJ, Dewey CF Jr, Gimbrone MA Jr. Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells. J Clin Invest 1994; 94: 885-91.
12. Lee RT, Yamamoto C, Feng Y, et al. Mechanical strain induces specific changes in the synthesis and organization of proteoglycans by vascular smooth muscle cells. J Biol Chem 2001; 276: 13847-51.
13. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Mol Cell 1998; 2: 275-81.
14. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-7.
15. Mach F, Sauty A, Iarossi AS, et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999; 104: 1041-50.
16. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apoliprotein E. Proc Natl Acad Sci USA 1995; 92: 8264-8.
17. Qiao JH, Tripathi J, Mishra NK, et al. Role of macrofage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997; 150: 1687-99.
18. Hansson G, Libby P: The role of the lymphocyte. In: Fuster V, Ross R, Topol E, eds Aterosclerosis and coronary artery disease. New York, NY: Lippincott-Raven, 1996: 557-68.
19. Libby P, Geng YJ, Aikawa M, et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996; 7: 330-5.
20. Libby P. Current concepts of the pathogenesis of the acute coronary syndrome. Circulation 2001; 104: 365-72.
21. Libby P, Simon DI. Inflammation and trombosis: the clot thickens. Circulation 2001; 103: 1718-20.
22. Andre P, Nannizzi-Alaimo L, Prasad KS, Philips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002, 106: 896-9.
23. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002, 8: 247-52.
24. Aukrust P, Waehre T, Damas JK, Gullestad L, Solum NO. Inflammatory role of platelets in acute coronary syndromes. Heart 2001 86: 605-6.
25. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001; 89: 1092-103.
26. Burke AP, Kolodgie FD, Farb A, Weber D, Virmani R. Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation 2002; 105: 297-303.
27. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
28. Mallat Z, Tedgui A. Current perspective on the role of apoptosis in the atherothrombotic disease. Circ Res 2001; 88: 998-1003.
29. Abbas AK, Lichtman AH, Pober JS. Immunologia cellulare e molecolare. Padova: Piccin Editore, 1994.
30. Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell 1994, 76: 253-62.
31. Uyemura K, Demer LL, Castle SC, et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97: 2130-8.
32. Qin S, Rottman JB, Myers P, et al. The chemokine receptor CXCR3 and CCR5 mark subset of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101: 746-54.
33. Hajjar DP, Haberland ME. Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. J Biol Chem 1997; 272: 22975-8.
34. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med 1999; 107: 85-97.
35. Lee TS, Yen HC, Pan CC, Chau LY. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19: 734-42.
36. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991; 11: 1223-30.
37. Geng YJ, Wu Q, Muszynski M, Hansson GK, Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler Thromb Vasc Biol 1996; 16: 19-27.
38. Fernandes JL, Mamoni RL, Orford JL, et al. Increased Th1 activity in patients with coronary artery disease. Cytokine 2004; 26: 131-7.
39. Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378: 88-91.
40. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-50.
41. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997; 99: 2752-61.
42. Dinarello CA, Novick D, Puren AJ, et al. Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leukoc Biol 1998; 63: 658-64.
43. Dinarello CA. Interleukin-18, a proinflammatory cytokine. Eur Cytokine Netw 2000; 11: 483-6.
44. McInnes IB, Gracie JA, Leung BP, Wei XQ, Liew FY. Interleukin 18: a pleiotropic participant in chronic inflammation. Immunol Today 2000; 21: 312-5.
45. Okamura H, Tsutsumi H, Kashiwamura S, Yoshimoto T, Nakanishi K. Interleukin-18: a novel cytokine that augments both innate and aquired immunity. Adv Immunol 1998; 70: 281-312.
46. Takeda K, Tsutsui H, Yoshimoto T, et al. Defective NL cell activity and Th1 response in IL-18-deficient nice. Immunity 1998; 8: 383-90.
47. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002; 195: 245-57.
48. Mallat Z, Corbaz A, Scoazec A, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104; 1598-603.
49. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res 2002; 90: E34-E38.
50. Mallat Z, Corbaz A, Scoazec A, et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001; 89: E41-E45.
51. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17-e24.
52. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF Kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995; 270: 9558-63.
53. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995; 96: 2304-10.
54. Lindmark E, Tenno T, Chen J, Siegbahn A. IL-10 inhibits LPS-induced human monocyte tissue factor expression in whole blood. Br J Haematol 1998; 102: 597-604.
55. Arai T, Hiromatsu K, Nishimura H, et al. Endogenous interleukin 10 prevents apoptosis in macrophages during Salmonella infection. Biochem Biophys Res Commun 1995; 213: 600-7.
56. Geng Y, Shane RB, Berencsi K, et al. Chlamydia pneumoniae inhibits apoptosis in human peripheral blood mononuclear cells through induction of IL-10. J Immunol 2000; 164: 5522-9.
57. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunctions: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-8.
58. Pinderski LJ, Fishbein MP, Subbanagounder G, et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002; 90: 1064-71.
59. Pinderski Oslund LJ, Hedrick CC, Olvera T, et al. Interleukin-10 blocks atherosclerosis events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 2847-53.
60. Yang Z, Zingarelli B, Szabo C. Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury. Circulation 2000; 101: 1019-26.
61. Hirano T. Interleukin-6 and its receptor: ten years later. Int Rev Immunol 1998; 16: 249-84.
62. Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000; 21: 1574-83.
63. Bossowska A, Kiersnowska-Rogowska B, Bossowski A, Galar B, Sowinski P. Cytokines in patients with ischaemic heart disease of myocardial infarction. Kardiol Pol 2003; 59: 105-14.
64. Pristipino C. Le citochine nella cardiopatia ischemica. Atti del corso di formazione. Citochine 2004, attualità nell'impiego clinico in area critica. Roma, 2005: 25-31.
65. Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 94: 874-7.
66. Manten A, de Winter RJ, Minnema MC, et al. Procoagulant and proinflammatory activity in acute coronary syndromes. Cardiovasc Res 1998; 40: 389-95.
67. Biasucci LM, Liuzzo G, Fantuzzi A, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999; 99: 2079-84.
68. Simon AD, Yazdani S, Wang W, Schwartz A, Rabbani LE. Circulating levels of IL-1beta, a prothrombotic cytokine, are elevated in unstable angina versus stable angina. J Thromb Thrombolysis 2000; 9: 217-22.
69. Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995; 92: 748-55.
70. Rifai N, Joubran R, Yu H, Asmi M, Jouma M. Inflammatory markers in men with angiographically documented coronary heart disease. Clin Chem 1999; 45: 1967-73.
71. Biasucci LM, Liuzzo G, Colizzi C, Rizzello V. Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease. Ital Heart J 2001; 2: 164-71.
72. Zhou RH, Shi Q, Gao HQ, Shen BJ. Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population. J Atheroscler Thromb 2001; 8: 30-2.
73. Yamashita H, Shimada K, Seki E, Mokuno H, Daida H. Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol 2003; 91: 133-6.
74. Mallat Z, Henry P, Fressonnet R, et al. Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart 2002; 88: 467-9.
75. Seta Y, Kanda T, Tanaka T, et al. Interleukin-18 in acute myocardial infarction. Heart 2000; 84: 668.
76. Blankenberg S, Tiret L, Bickel C, for the AtheroGene Investigators. Interleukin-18 is a strong predictor of cardiovascular death in stable angina and unstable angina. Circulation 2002: 106: 24-30.
77. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 2001; 104: 746-9.
78. Heeschen C, Dimmeler S, Hamm CW, for the CAPTURE Study Investigators. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003; 107: 2109-14.
79. Waehre T, Halvorsen B, Damas JK, et al. Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest 2002; 32: 803-10.
80. Wan S, Yim AP. Cytokines in myocardial injury: impact on cardiac surgical approach. Eur J Cardiothorac Surg 1999; 16 (Suppl 1): S107-S111.
81. Herrera Garza E, Herrera Garza JL, Rodriguez Gonzales H, Trevino Trevino A, Ibarra Flores M, Torre Amione G. Importance of tumor necrosis factor-alpha in the pathogenesis of heart failure. Rev Esp Cardiol 2002; 55: 61-6.
82. Patti G, D'Ambrosio A, Mega S, et al. Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction. J Am Coll Cardiol 2004; 43: 35-8.
83. Patti G, Mega S, Pasceri V, et al. Interleukin-1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction. Clin Cardiol 2005; 28: 193-6.
84. Patti G, Di Sciascio G, D'Ambrosio A, Dicuonzo G, Abbate A, Dobrina A. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol 2002; 89: 372-6.
85. Patti G, Di Sciascio G, D'Ambrosio A, Dicuonzo G, Abbate A, Dobrina A. Inflammatory markers and coronary interventions: a potentially useful follow-up modality after stenting. Catheter Cardiovasc Interv 2002; 56: 341-5.
86. Mizia-Stec K, Gasior Z, Zahorska-Markiewicz B, et al. Serum tumour necrosis factor-alpha, interleukin-2 and interleukin-10 activation in stable angina and acute coronary syndromes. Coron Artery Dis 2003; 14: 431-8.
87. Mazzone A, De Servi S, Vezzoli M, et al. Plasma levels of interleukin 2, 6, 10 and phenotypic characterization of circulating T lymphocytes in ischemic heart disease. Atherosclerosis 1999; 145: 369-74.
88. Simon AD, Yazdani S, Wang W, Schwartz A, Rabbani LE. Elevated plasma levels of interleukin-2 and soluble IL-2 receptor in ischemic heart disease. Clin Cardiol 2001; 24: 253-6.
89. Tokac M, Ozeren A, Aktan M, et al. The role of inflammation markers in triggering acute coronary events. Heart Vessels 2003; 18: 171-6.
90. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106: 1447-52.
91. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
92. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-33.
93. Ostadal P, Alan D, Hajek P, et al. The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q wave myocardial infarction. Mol Cell Biochem 2003; 246: 45-50.
94. Gonzalvez M, Ruiz Ros JA, Perez-Paredes M, et al. Effect of the early administration of pravastatin on C-reactive protein and interleukin-6 levels in the acute phase of myocardial infarction with ST segment elevation. Rev Esp Cardiol 2004; 57: 916-23.
95. Kinlay S, Schwartz GG, Olsson AG, for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108: 1560-6.